Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Balancing Opioid Addiction Risk with Pain Management Needs

Larry Beresford  |  Issue: February 2018  |  February 18, 2018

At the same time, 2 million Americans today are addicted to opioids. In April 2017, Thomas E. Price, MD, Secretary of the DHHS, announced a five-pronged national strategy to combat the opioid crisis, including:

  • Improving access to treatment and recovery services;
  • Promoting the use of overdose-reducing drugs (such as naloxone);
  • Strengthening our understanding of the epidemic through better public health surveillance;
  • Supporting cutting-edge research on pain and addiction; and
  • Advancing better practices for pain management.

The Pain Management Best Practices Inter-Agency Task Force is pulling together federal and nonfederal partners from a broad range of interests, including providers, pain advocacy groups, veterans’ services organizations, the Department of Defense and the Office of National Drug Control Policy. Its charge: Identify gaps in pain management best practices, recommend how to address them and disseminate information about those best practices. Nominations for the Inter-Agency Task Force were accepted through Sept. 27, and the DHHS is currently reviewing applications for the Task Force.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

‘We have an opioid problem, & we have a pain problem, & we believe there’s a need to develop new pain therapies.’ —Dr. Porter

Research Priorities

Research into better, safer pain management and the fundamental understanding of pain remains an essential part of the pain puzzle. The 2017 Federal Pain Research Strategy was developed by the NIH Office of Pain Policy, with oversight by the Interagency Pain Research Coordinating Committee, a federal advisory committee created by the DHHS to enhance pain research efforts and promote collaboration across government agencies. This plan fulfills mandates in the Affordable Care Act while aiming to avoid duplication of federal pain research efforts. It has identified five research priority areas, as well as opportunities to apply Common Fund Support (a source of federal dollars in the Office of the Director at NIH) for transformative projects too big for one institute, Dr. Porter said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The government’s research strategy also includes publications, public–private partnerships and research to address the opioid use disorder crisis. Delivery targets include enhancing the evidence base for pain care and integrating it into clinical practice. The Agency for Healthcare Research and Quality is driving a systematic review of evidence-based nonpharmacological pain treatments, from acupuncture to exercise, Dr. Singh noted. The government is also developing an online pain education portal and trying to standardize comprehensive pain assessments and outcome measures.

Charles (Chad) G. Helmick, MD, medical epidemiologist in the Arthritis Program at the Centers for Disease Control and Prevention, said a lot is going on in the pain arena at the federal level. It’s not just the opioid crisis, with increasing fatalities affecting all demographic groups, he said, but also recognition that the current pain management system is dysfunctional. Much of the pain experienced by Americans is musculoskeletal, either due to arthritis or low back pain.

Page: 1 2 3 | Single Page
Share: 

Filed under:AnalgesicsDrug UpdatesEthicsLegal UpdatesMeeting Reports Tagged with:ACR/ARHP Annual Meetingopioid epidemicPain Management

Related Articles
    ah_designs / shutterstock.com

    The Perils of Pain Meds Revisited

    December 18, 2018

    More than 10 years ago, I wrote a commentary in The Rheumatologist, called “Perils of Pain Meds,” about the over-prescribing of opioid analgesics for common causes of chronic noncancer pain, which was a major contributor to the opioid epidemic.1 Since that time, although there has been a greater than 20% decrease in opioid prescribing, the…

    Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?

    November 4, 2022

    I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Rheumatologists Respond to Prescription Opioid Analgesic Crisis

    May 16, 2017

    The alarming statistics on prescription opioid overdoses are well known to medical professionals, thanks to the Centers for Disease Control and Prevention (CDC)’s widely cited finding that deaths from opioid analgesics have increased fourfold since 1999.1 Half of all fatal drug overdoses now involve opioids prescribed by a doctor. Meanwhile, a lack of rigorous research…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences